Abstract
The aim of this study was to evaluate the effectiveness of IL-1 inhibition in rheumatic disease using real-life, observational methods. We analyzed data from 47 patients collected from the national ROB-FIN for rheumatic disease. Commonly used, validated measures of efficacy and adverse effects were documented and analyzed. The series contains 47/1,135 patients (mean age 47±11 years, range 25–73, females 83%) on anakinra of whom 39 patients suffered from rheumatoid arthritis (RA), two presented with psoriatic arthritis, and four with juvenile RA. At 3 months (26/40), 46% reached American College of Rheumatology (ACR) 20 and 27% ACR 50. In patients naive to biological drugs, the response rate at 3 months was 60% for ACR 20 and 20% for ACR 50. At follow-up of the total series, ACR responses at 6 and 12 months were 69/56% for ACR 20 and 23/22% for ACR 50. These data give room for IL-1 suppression when treating patient with rheumatic disease. Careful selection of patients, together with combining anakinra with disease-modifying antirheumatic drugs, perhaps adds effectiveness. For treating clinicians in Finland, these results are encouraging, as reimbursed treatment alternatives for patients refractory to all other therapies are still few.
This is a preview of subscription content, log in via an institution to check access.
References
Buch MH, Bingham SJ, Seto Y, McGonagle D, Bejarno V, White J et al (2004) Lack of response to anakinra in rheumatoid arthritis following of tumor necrosis factor alpha blockade. Arthritis Rheum 50:725–728
Saxne T, Larsson L, Geborek P (2004) Results of anakinra treatment in rheumatoid arthritis patients previously treated with tumor necrosis alpha blockade: comment on the article by Buch et al. Arthritis Rheum 50:3049–3050
Schiff MH, Keystone EC, Gibofsky A, Markenson JA, Weaver A, Xia HA et al (2004) Efficacy of Anakinra in patients with rheumatoid arthritis previously refractory to TNF antagonists. ACR 2004, abstract 920
Langer HE, Missler-Karger B (2003) Kineret: efficacy and safety in daily clinical practice: an interim analysis of the Kineret response assessment initiative (Kreative) protocol. Int J Clin Pharm Res 4:119–128
Den Broeder AA, de Jong E, Franssen MJ, Jeurissen ME, Flendrie M, van den Hoogen FH (2005) Observational study on efficacy, safety and drug-survival of anakinra in RA patients in clinical practice. Ann Rheum Dis [Epubl ahead of print]
Nordström D, Konttinen L, Korpela M, Tiipana-Kinnunen T, Eklund K, Forsberg S et al (2005) Performance study of patients using traditional anti-rheumatic drugs in combination with infliximab: The Finnish perspective. Rheumatol Int [Epubl ahead of print]
Breshnihan B, Alvaro-Gracia J, Cobby M, Doherty M, Domljan Z, Emery P et al (1998) Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 41:2196–2204
Cohen SB, Wooley JM, Chan W (2003) Interleukin 1 receptor antagonist anakinra improves functional status in patients with rheumatoid arthritis. J Rheumatol 30:225–231
Tessler J, Fleischman R, Dore R, Bennett R, Solinger A, Joh T et al (2004) Concomitant medication use in a large, international, multicenter, placebo controlled trial on anakinra, a recombinant interleukin-1 receptor antagonist, in patients with rheumatoid arthritis. J Rheumatol 31:649–654
Acknowledgements
The expert data processing and statistical assistance by Dr. Viljami Laine and secretarial assistance by Secretary Taina Käyhkö are greatly appreciated. This study has been supported by Finska Läkaresällskapet and the Perklen and Viktoria Foundations. The Fin-ROB register has been financially supported by grants from Schering-Plough, Wyeth, Amgen, Abbott, and Biovitrum.
Author information
Authors and Affiliations
Consortia
Corresponding author
Rights and permissions
About this article
Cite this article
Konttinen, L., Kankaanpää, E., Luosujärvi, R. et al. Effectiveness of anakinra in rheumatic disease in patients naive to biological drugs or previously on TNF blocking drugs: an observational study. Clin Rheumatol 25, 882–884 (2006). https://doi.org/10.1007/s10067-006-00243-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-006-00243-0